The choice of the azoxymethane/dextran sulphate sodium model is significant for interpreting these findings. This two-step protocol first exposes mice to a genotoxic carcinogen and then subjects them to repeated cycles of colonic epithelial injury and repair, producing tumours that arise on a background of chronic inflammation. That sequence mirrors one of the recognised pathways of human colorectal carcinogenesis, in which persistent inflammatory conditions such as colitis precede and promote malignant transformation. Because inflammation is not merely a by-product but an active driver in this model, interventions that dampen inflammatory signalling can be evaluated for their potential to interrupt the tumour-promoting feed-forward loop between tissue damage, immune activation, and epithelial proliferation.

Interleukin-6 occupies a central position in this loop. Produced by epithelial cells, macrophages, and other immune populations in the gut, it activates signalling pathways that promote epithelial cell survival, proliferation, and resistance to apoptosis, thereby creating conditions favourable for tumour expansion. The observation that menaquinone-7 supplementation and supplementation with the vitamin K2-producing Lactobacillus plantarum strain both reduced interleukin-6 levels therefore points to a plausible mechanistic target. The concurrent improvement in the localisation of interleukin-10, an anti-inflammatory cytokine, suggests a rebalancing of the mucosal immune environment rather than simple global immunosuppression, which would be an undesirable outcome in a cancer context.

The elevated interleukin-10 seen in untreated AOM/DSS-control mice deserves particular attention. Although interleukin-10 is generally regarded as protective and anti-inflammatory, tumours can co-opt immunosuppressive cytokine networks to build a microenvironment that shields malignant cells from effective immune surveillance. The pattern observed in the control animals, with elevated interleukin-10 accompanying chronic mucosal inflammation and glandular distortion, is consistent with the establishment of such an immunosuppressive tumour microenvironment. The shift toward more homeostatic interleukin-10 distribution in the treated groups may therefore reflect a normalisation of immune regulation rather than a simple increase or decrease in any single cytokine.

The nuclear factor kappa B pathway provides a candidate molecular link between the vitamin K2 interventions and the cytokine changes measured in the study. This transcription factor family sits upstream of many inflammatory genes, including those encoding interleukin-6, interleukin-8, and tumour necrosis factor alpha, and its constitutive activation is a well-documented feature of inflammation-associated cancers. Inhibition of this pathway can therefore cascade into coordinated reductions across multiple pro-inflammatory mediators, which is the pattern the authors observed across all vitamin K2 interventions. Confirming this mechanism definitively in vivo would require additional experimentation, but the consistency of the cytokine modulation across homologues with very different absorption profiles lends indirect support to a pathway-level effect.

The microbiological dimension of the study adds a layer of complexity that distinguishes it from simple nutraceutical experiments. By combining next-generation sequencing with classical culture methods, the researchers could track both the overall composition of the gut community and the abundance of specific Lactobacillus species. The finding that menaquinone-9 supplementation markedly increased faecal Lactobacillus abundance despite its poor absorption raises the possibility that this long-chain homologue acts partly as a substrate or selective factor favouring lactobacilli in the lumen. If so, the anti-inflammatory activity of menaquinone-9 could be mediated at least in part through reshaping the microbial community rather than through direct effects on host tissue, an interpretation that would align with the growing recognition that microbiota composition is itself a modifiable determinant of colonic inflammation.

The use of a naturally produced form of vitamin K2, generated by a Lactobacillus plantarum strain rather than supplied as a purified synthetic compound, bridges two research traditions that have largely developed in parallel: probiotic therapy and vitamin-based chemoprevention. Certain intestinal bacteria, lactobacilli among them, are known to synthesise menaquinones, and the study’s design allowed the authors to compare a bacterial source of the vitamin with chemically defined homologues. The comparable anti-inflammatory effects observed with the natural preparation and with menaquinone-7 suggest that the bioactive molecule, rather than the delivery vehicle, drives much of the effect, although the probiotic strain may contribute additional benefits through its own interactions with the mucosal immune system.

Methodologically, the quantification of menaquinones by ultra-pressure liquid chromatography coupled to tandem mass spectrometry with atmospheric pressure chemical ionisation represents an important strength. Vitamin K2 homologues are hydrophobic molecules that differ only subtly in side-chain length, making their separate quantification in complex biological matrices technically demanding. The ability to measure individual homologues in both faeces and colonic homogenates is what made it possible to detect the divergent absorption behaviours of menaquinone-4, -7, and -9, a distinction that would have been invisible if only total vitamin K activity had been assessed. The supplementary detection of menaquinone-5 and menaquinone-6 in these samples further indicates that the analytical method captured intermediate homologues, with menaquinone-5 in the colon falling below the limit of detection in all groups.

The immunofluorescence and western blotting approaches used to profile cytokine expression complement each other in a useful way. Immunofluorescence preserves spatial information, revealing where within the mucosal architecture a given cytokine is being produced, which is essential for interpreting changes in the tumour microenvironment where immune cells, epithelial cells, and stromal components are unevenly distributed. Western blotting provides quantitative protein-level confirmation. Together these methods allowed the authors to describe not just how much of each cytokine was present but how its distribution across the tissue changed with treatment, which is how the improved localisation of interleukin-10 was identified.

It is worth emphasising what the mouse model can and cannot establish. The AOM/DSS protocol reliably reproduces inflammation-driven colonic tumorigenesis and is widely used for preclinical chemoprevention research, but the inflammatory and microbial context of the laboratory mouse differs from that of human patients, whose tumours arise over decades against a backdrop of individual diet, microbiota, and immune history. The BALB/c strain used here is an inbred line, which reduces variability within the experiment but also limits the genetic diversity over which the findings can be generalised. Translating these results into human chemoprevention strategies will require studies that account for human microbiome variability, dietary vitamin K intake, and the pharmacokinetics of menaquinone supplementation in people with existing colonic pathology.

The dosing and formulation details recorded in the supplementary materials, including the composition of the purified diets and the preparation procedures for each homologue, matter for reproducibility and for future comparative work. Because menaquinones are fat-soluble and vary in bioavailability depending on the vehicle and dietary matrix, standardised dietary composition is essential when comparing interventions across laboratories. The documentation of these procedures, together with the semi-quantitative histopathological scoring criteria for mucosal and submucosal damage, provides a framework that other groups can adopt when testing related interventions.

The collaborative structure of the research team reflects the multidisciplinary demands of this kind of study. Microbiologists at Jagiellonian University Medical College handled the bacterial strain characterisation and culture work, veterinary scientists contributed to the animal model, analytical chemists developed the mass spectrometric quantification of menaquinones, oncologists and cancer metabolism researchers contributed expertise on the tumour biology, and pathologists performed the histopathological assessment. This breadth was necessary because the central question, whether a bacterial vitamin can modulate inflammation in a way that alters cancer-relevant biology, spans microbiology, nutrition, immunology, and oncology simultaneously.

Looking forward, several questions follow naturally from these findings. Whether the cytokine modulation observed during the intervention translates into reduced tumour burden or improved survival in longer-term follow-up is a critical next step. Whether the NF-kappa B pathway inhibition is direct or mediated through upstream changes in the microbiota or in epithelial barrier function remains to be resolved. And whether the homologue-specific differences in absorption and microbiota effects persist in animals with more diverse microbial communities, or in humans, will determine which menaquinone, if any, is best suited for chemoprevention trials. The open access publication of this work, funded by the National Science Centre Poland, ensures that these questions can be pursued by any laboratory with the appropriate model systems and analytical capabilities.

Subject of Research: colorectal cancer

Article Title: Anti-inflammatory effects of vitamin K2 and Lactobacillus plantarum in a mouse model of colorectal cancer

Article References: Strus, M., Wójcik, A., Gruszka, A. M., Meyger, Ł., Kuziak, A., Kasperski, T., Arent, Z., Pardyak, L., Dubniewicz, K., Baś, B., Piwowar, P., Żeber-Lubecka, N., Kij, A., Okoń, K., Stanek, M., & Jedlińska, K. (2026). Anti-inflammatory effects of vitamin K2 and Lactobacillus plantarum in a mouse model of colorectal cancer. BMC Biology. https://doi.org/10.1186/s12915-026-02742-0

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02742-0

Keywords: vitamin K2, menaquinones, Lactobacillus plantarum, colorectal cancer, gut microbiota, cytokines, NF-κB, mouse model, probiotics, chemoprevention, Anti-inflammatory, effects

NDMA is one of the most extensively studied nitrosamine carcinogens. It appears in preserved and smoked foods, in contaminated drinking water, and it made international headlines when it was found in batches of the blood pressure drug valsartan and the heartburn medication ranitidine. The liver is its principal target organ, and prolonged low-dose exposure is known to predispose both animals and humans to hepatocellular carcinoma, the most common form of primary liver cancer, which accounts for roughly ninety percent of such cases and remains a leading cause of cancer mortality worldwide. Yet the question of whether NDMA does more than damage DNA — whether it can actively generate the self-renewing, treatment-resistant cells that make liver tumors so hard to eradicate — had remained unresolved.

To address this, the team, led by researchers at Nanjing Medical University, Ningbo No. 2 Hospital, and Sun Yat-sen University Cancer Center, exposed the non-cancerous human liver cell line LO2 to low concentrations of NDMA continuously for thirty passages, a period of about three months. The cells that received the higher dose, one microgram per milliliter, transformed dramatically. They became irregular and spindle-shaped, proliferated faster, migrated and invaded more aggressively than even the established liver cancer line Huh-7 used as a positive control, and showed elevated levels of hepatocellular carcinoma markers such as AFP, GGT1, and GSTP1 alongside a shift toward mesenchymal proteins like vimentin and N-cadherin, a hallmark of epithelial-mesenchymal transition. The researchers designated these cells TLO2 and used them as their experimental model of NDMA-driven liver cancer.

When the transformed cells were cultured in serum-free medium — a standard technique for enriching cancer stem cells — they formed large, abundant spherical clusters, a sign of self-renewal capacity. Flow cytometry revealed that roughly a quarter more cells expressed CD133, a well-established liver cancer stem cell marker, after this enrichment. Levels of additional stemness markers, including SOX2, OCT4, and EPCAM, rose in parallel. Soft agar and colony formation assays confirmed that the NDMA-transformed cells could grow without a solid substrate and form colonies at rates comparable to mature liver cancer cells. In short, chronic NDMA exposure did not merely convert liver cells into tumor-like cells; it endowed them with the stem-like properties that fuel metastasis, recurrence, and drug resistance.

The study then turned to ZNF652, a zinc finger transcription factor that previous work had linked to tumor suppression in several cancers. Database analyses using KM-PLOTTER and TNMplot showed that higher ZNF652 expression correlated with better survival in hepatocellular carcinoma patients, and that ZNF652 levels were lower in metastatic lesions than in primary tumors. In the NDMA-transformed cells, ZNF652 protein dropped after sphere enrichment. When the researchers forced ZNF652 back into the cells, spheres became smaller and less frequent, and the stemness markers CD133, SOX2, OCT4, and EPCAM all declined. Conversely, silencing ZNF652 with siRNA produced larger, more numerous spheres and higher marker expression. These results positioned ZNF652 as a brake on liver cancer stemness.

The Sonic Hedgehog pathway, a classical developmental signaling cascade that is frequently hijacked in cancer, emerged as the mechanism through which ZNF652 acts. Database comparisons showed that key components of the pathway — SHH, SMO, GLI1, and GLI2 — were elevated in liver cancer tissue relative to normal liver, and that they rose further when the transformed cells were enriched for stemness. GLI1, the transcriptional effector that translocates to the nucleus to activate Hedgehog target genes, proved particularly consequential: overexpressing it increased sphere size and frequency and boosted stemness markers, while knocking it down had the opposite effect. The pathway, in other words, actively promotes the cancer stem cell state in these cells.

The pivotal finding came when the team connected the two molecules. Correlation analyses revealed a negative relationship between ZNF652 and the Hedgehog components, and manipulating ZNF652 levels produced reciprocal changes in SHH, SMO, GLI1, and GLI2 expression. Using the JASPAR database, the researchers identified potential ZNF652 binding sites in the GLI1 promoter, then confirmed with dual-luciferase reporter assays that ZNF652 overexpression suppressed GLI1 transcriptional activity. Rescue experiments sealed the logic: when GLI1 was artificially raised, adding ZNF652 brought CD133 expression back down, and when ZNF652 was knocked down, reducing GLI1 reversed the resulting increase in stemness. ZNF652, the data showed, directly targets GLI1 to restrain the Hedgehog-driven cancer stem cell program.

Sulforaphane entered the picture as the pharmacological lever on this axis. The compound, produced when the enzyme myrosinase converts glucoraphanin in broccoli and other cruciferous vegetables, has long been known for anti-inflammatory, antioxidant, and anticancer properties, and ongoing clinical trials have explored its ability to inhibit cancer development. In the new study, treating the transformed cells with sulforaphane at concentrations of one, three, and five micromolar reduced sphere size and frequency, suppressed colony formation, and diminished self-renewal capacity as measured by extreme limiting dilution analysis. Western blots showed dose-dependent declines in CD133, SOX2, OCT4, and EPCAM, and immunofluorescence confirmed reduced CD133 signal. Crucially, sulforaphane also lowered the Hedgehog pathway components and raised ZNF652, and it reversed the stemness increase caused by either GLI1 overexpression or ZNF652 knockdown — evidence that the compound works through the same axis it was suspected of modulating.

To test whether these effects held in living tissue, the researchers implanted NDMA-pretreated Huh-7 cells subcutaneously into twenty female BALB/c nude mice, dividing them into control, NDMA-exposed, and two sulforaphane treatment groups receiving twelve point five or twenty-five milligrams per kilogram by oral gavage twice weekly for four weeks. Tumors in the NDMA group grew significantly larger than controls, while both sulforaphane doses reduced tumor volume and weight in a dose-dependent manner. Immunohistochemistry on excised tumors showed that NDMA exposure elevated CD133 and GLI1 while suppressing ZNF652, and that sulforaphane reversed all three changes, restoring ZNF652 and lowering the stemness and Hedgehog markers.

The authors acknowledge limitations: the xenograft model relied on cells pretreated with NDMA before implantation rather than systemic exposure in the animals, so it may not fully reproduce the natural course of NDMA-associated hepatocarcinogenesis or the complexity of the liver microenvironment, and the human database findings are correlative and were not validated in independent patient cohorts. Even so, the study offers a coherent mechanistic account of how a dietary carcinogen can generate the cellular seeds of liver cancer recurrence, and how a compound found in everyday vegetables can disrupt that process at its molecular root. If confirmed in clinical settings, targeting the ZNF652–GLI1 axis could open a new avenue for preventing or treating hepatocellular carcinoma, particularly in populations with high nitrosamine exposure.

Subject of Research: Sulforaphane inhibition of NDMA-induced hepatocellular carcinoma stem cell properties via the ZNF652/Sonic Hedgehog axis

Article Title: Sulforaphane inhibits N-nitrosodimethylamine induced hepatocellular carcinoma stem cell properties via ZNF652/Sonic hedgehog axis

Article References: Wu, J., Wang, X., Ren, D., Jiang, D., He, L., Chen, Y., Zhong, C., Li, X., & Han, H. (2026). Sulforaphane inhibits N-nitrosodimethylamine induced hepatocellular carcinoma stem cell properties via ZNF652/Sonic hedgehog axis. Frontiers in Cell and Developmental Biology, 14, Article 1965529. https://doi.org/10.3389/fcell.2026.1965529

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1965529

Keywords: sulforaphane, NDMA, hepatocellular carcinoma, cancer stem cells, ZNF652, Sonic Hedgehog, GLI1, broccoli, liver cancer, chemoprevention, CD133, nitrosamines

The scale of the underlying registry is enormous. ClinicalTrials.gov, maintained by the U.S. National Library of Medicine, now hosts more than 345,000 interventional and observational studies and serves as the de facto public record of clinical research activity. But the new analysis, led by Martha Fors of Universidad de Las Américas in Quito, Ecuador, zeroed in on a specific and increasingly important niche: studies designed to stop cancer before it becomes clinically manifest invasive disease. Using search terms spanning chemoprevention, premalignant lesions, precursor conditions, carcinoma in situ, dysplasia, and minimal residual disease, the team assembled a picture of how prevention-oriented science is actually being conducted and, crucially, how it is being labeled.

The concept of cancer interception sits in a biological no-man’s-land between prevention and treatment. Primary prevention targets healthy individuals at risk, aiming to stop the carcinogenic process before it starts. Screening and early detection seek to find existing occult tumors or precursor lesions sooner. Interception, by contrast, intervenes on a measurable biological state, a molecular abnormality, an inherited predisposition, or a histological premalignant lesion, with the goal of halting or reversing progression before invasive cancer develops. A recent framework in Cancer Discovery formalized this spectrum as cancer prophylaxis, interception, and mitigation, but the new study shows that registry infrastructure has not caught up with the science.

The numbers tell a striking story. Of the 209 eligible studies, 157, or 75.1 percent, were interventional and 52 were observational. Just over half, 52.6 percent, had been completed. Among the interventional trials, randomized allocation dominated at 66.9 percent, parallel-group designs accounted for 65 percent, and most studies, 65 percent, were unmasked or open-label. Median estimated enrollment was 150 participants with a wide interquartile range of 61.5 to 533.5, reflecting everything from small biomarker studies to large prevention cohorts. Gynecological and gastrointestinal malignancies led the representation, at 25.4 and 23.4 percent respectively.

That anatomical concentration is not accidental. The authors argue that it reflects a fundamental methodological asymmetry in oncology research. Cervical intraepithelial neoplasia and colorectal adenomas are well-characterized precursor states with identifiable biomarkers, offering feasible endpoints for interception trials within reasonable follow-up periods. For cancers whose earliest biological changes remain elusive or clinically occult, the barrier to designing reproducible interception studies remains high. The registry landscape, in other words, is heavily biased toward what the researchers call high-feasibility biological pathways, potentially leaving unmet needs in less-defined interception domains poorly addressed.

Perhaps the most consequential finding concerns classification. When the team applied an operational framework dividing interventional studies into three categories, primary prevention and chemoprevention, early detection and diagnosis, and cancer interception with post-treatment disease control, the distribution was nearly even: 32.5 percent, 34.4 percent, and 33.1 percent respectively. But only the first two categories have native registry designations, mapping to ClinicalTrials.gov’s Prevention, Screening, and Diagnostic fields. The 52 interception and post-treatment disease-control studies, roughly a third of the interventional portfolio, had no distinct registry home at all, and were scattered across broad categories such as Supportive Care, Basic Science, and Health Services Research.

This structural ambiguity has practical consequences. Interception research often involves populations that are neither healthy individuals in primary prevention nor patients with established cancer, but rather people carrying inherited risk, molecular abnormalities, or precursor lesions. Registry fields that fail to capture these intermediate states obscure the true scope of preventive research, hinder evidence synthesis, and complicate any attempt to quantify global progress in the field. The problem extends to study phase as well: 86 percent of the interventional trials were classified as Not Applicable for phase, because conventional phase I through IV categories were designed for therapeutic drug development and fit poorly with behavioral interventions, devices, nutritional components, and long-term biomarker endpoints.

Funding transparency fared even worse. A staggering 87.6 percent of records, 183 of 209, were classified under the registry’s generic Other funding category, with industry funding at just 6.7 percent and NIH funding at 2.4 percent. Because ClinicalTrials.gov does not disclose the institutional nature of funders coded as Other, the researchers could not determine whether these studies rely on philanthropic capital, academic institutional budgets, or cooperative group support, and any manual attribution would have risked substantial misclassification. A statistically significant association between study type and funding category emerged, p equal to 0.028 with a small Cramér’s V of 0.25, but the authors caution it reflects registry structure rather than a defined investment pattern. Notably, 25.8 percent of studies were restricted to female participants, largely mirroring the gynecological focus.

The team’s proposed remedies are concrete. They call for a dedicated Prevention/Interception Stage classification distinguishing primary prevention, biological interception, and post-treatment control; mandatory disaggregation of funding sources into philanthropic, academic institutional, cooperative group, and industry categories; a structured metadata field for baseline biological or risk status capturing genetic, molecular, or histopathological markers; and standardized tagging of primary trial objective to cleanly separate early detection from progression interruption. Such refinements, they argue, would improve visibility, traceability, and cross-trial comparability in preventive oncology.

The study carries its own caveats, which the authors are careful to spell out. Restricting the analysis to ClinicalTrials.gov introduces geographic and structural bias toward North American research networks, and trials registered exclusively in the EU Clinical Trials Information System, the Japan Registry of Clinical Trials, or the WHO ICTRP network were not captured. Whether adopting prevention-specific metadata fields would actually accelerate clinical translation of interception research remains a hypothesis for future evaluation. Still, the message lands with force: cancer interception has matured into a distinct clinical discipline, and the registries that index human research have not yet learned to see it. Until they do, a third of the field’s clinical trials will remain scattered across categories that describe everything except what these studies are actually trying to do.

Subject of Research: Registry-based landscape analysis of cancer prevention and interception trials on ClinicalTrials.gov

Article Title: Cancer prevention and interception studies registered in ClinicalTrials.gov: a landscape analysis of trial characteristics and reporting gaps

Article References: Fors, M., González, P., Torres, A., Silva-Guayasamín, L., & Silva-Sarabia, C. (2026). Cancer prevention and interception studies registered in ClinicalTrials.gov: a landscape analysis of trial characteristics and reporting gaps. Frontiers in Epidemiology, 6, Article 1943268. https://doi.org/10.3389/fepid.2026.1943268

Image Credits: AI Generated

DOI: 10.3389/fepid.2026.1943268

Keywords: cancer interception, cancer prevention, chemoprevention, ClinicalTrials.gov, clinical trial registries, premalignant lesions, minimal residual disease, preventive oncology, trial metadata, funding transparency, early detection, epidemiology

The research, led by Doris Olachi Alilonu and colleagues at the Toxicology and Immunotherapy Research Unit of Alex-Ekwueme Federal University in Nigeria, focused on two distinct preparations from papaya leaves: a simple aqueous extract (AqCE) and a flavonoid-rich extract (FRE). Flavonoids are a diverse class of plant secondary metabolites known for their antioxidant and anti-inflammatory properties, and the team wanted to determine whether concentrating these compounds would enhance the protective effect against carcinogenesis.

To model breast cancer, the researchers used 7,12-dimethylbenz[a]anthracene, or DMBA, a well-established carcinogen that reliably induces mammary tumors in female Wistar rats. Thirty-five adult female rats were divided into seven groups: a vehicle control receiving 1% Tween 80, a DMBA-only disease group, a DMBA group treated with the standard chemotherapy drug cyclophosphamide at 20 mg/kg, and four treatment groups receiving either the aqueous extract at 250 or 500 mg/kg or the flavonoid-rich extract at 150 or 300 mg/kg. All treatments were delivered by oral gavage twice weekly over a 17-week experimental period, a design that allowed the researchers to observe both tumor development and the effects of concurrent extract administration.

The results were striking. DMBA exposure caused a significant drop in CD4+ T-cell counts, a key indicator of weakened cellular immunity, while simultaneously elevating the activity of two immunosuppressive enzymes: tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO). These enzymes break down the essential amino acid tryptophan, and their upregulation is a well-known strategy by which tumors escape immune surveillance. By depleting tryptophan in the tumor microenvironment, TDO and IDO effectively starve cytotoxic T cells of the fuel they need to attack cancer cells, creating a shield of immune tolerance around the growing tumor.

Both papaya leaf extracts reversed this immunosuppressive cascade. Rats treated with AqCE or FRE showed restored CD4+ counts, reduced TDO and IDO activity, and normalized levels of pro-inflammatory cytokines that had been elevated by DMBA. The extracts also corrected the oxidative stress imbalance caused by the carcinogen, bringing antioxidant parameters back toward baseline values. Perhaps most importantly for the clinical picture, the extracts significantly reduced tumor biomarkers that DMBA had driven upward, indicating a measurable dampening of the malignant process itself.

Histopathological examination provided visual confirmation of these biochemical findings. Mammary tissue from DMBA-exposed rats showed the hallmarks of severe invasive ductal carcinoma, the most common form of breast cancer in humans. In contrast, tissue from rats co-treated with the papaya leaf extracts displayed markedly attenuated malignant changes, with mammary architecture largely preserved. This structural protection suggests that the extracts are not merely masking biomarker changes but are genuinely interfering with the carcinogenic process at the tissue level.

To understand which specific molecules might be responsible, the team performed phytochemical profiling of the flavonoid-rich extract and identified five bioactive flavonoids. They then used molecular docking, a computational technique that predicts how small molecules fit into the active sites of target proteins, to test whether these flavonoids could interact with TDO and IDO. The docking results suggested stable and energetically favorable binding of the papaya flavonoids to both enzymes, consistent with potential inhibitory activity. This computational evidence provides a plausible molecular explanation for the reduced TDO and IDO activity observed in the treated animals and offers a rational starting point for future drug design efforts.

The multi-targeted nature of the observed effects is what makes this study particularly compelling. Rather than hitting a single pathway, the papaya leaf extracts appear to simultaneously bolster immune competence, suppress inflammatory signaling, restore antioxidant balance, inhibit immunosuppressive enzyme activity, and reduce tumor burden. This broad-spectrum profile mirrors the kind of holistic intervention that chemoprevention researchers have long sought, and it aligns with the growing interest in natural products as sources of structurally novel bioactive compounds.

The authors suggest that their findings position Carica papaya leaf extracts as potential candidates for plant-based immunotherapy, a field that has exploded in prominence with the success of immune checkpoint inhibitors but still faces challenges related to cost, accessibility, and side effects. A readily available agricultural byproduct with immunomodulatory and chemopreventive properties could offer a complementary or adjunctive approach, particularly in regions where papaya is widely cultivated and conventional therapies remain financially out of reach for many patients.

Nevertheless, important caveats remain. This study was conducted in a rodent model over a defined timeframe, and the doses used in rats cannot be directly translated to human consumption without careful dose-ranging and safety studies. The identity and pharmacokinetics of the five quantified flavonoids in vivo, their bioavailability after oral gavage, and their long-term toxicity profile all require further investigation. Clinical trials in humans would be the necessary next step before any recommendation regarding papaya leaf preparations could be made for cancer prevention or treatment. Still, the convergence of in vivo efficacy, histological protection, and computational mechanistic support makes this work a noteworthy addition to the expanding literature on dietary phytochemicals and cancer immunology, and it underscores how traditional ethnobotanical knowledge can guide the discovery of modern therapeutic leads.

Subject of Research: Chemopreventive and immunomodulatory effects of Carica papaya leaf extracts against DMBA-induced breast cancer in rats

Article Title: Aqueous and flavonoid-rich Carica papaya leaf extracts modulate 7, 12-dimethylbenz[a]anthracene-induced breast carcinogenesis in rats: roles of oxidative stress, inflammation, and in silico docking

Article References: Alilonu, D. O., Elom, S. O., Ebokaiwe, A. P., & Ajayi, A. A. (2026). Aqueous and flavonoid-rich Carica papaya leaf extracts modulate 7, 12-dimethylbenz[a]anthracene-induced breast carcinogenesis in rats: roles of oxidative stress, inflammation, and in silico docking. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06622-6

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06622-6

Keywords: Carica papaya, breast cancer, chemoprevention, flavonoids, DMBA, immunotherapy, indoleamine 2,3-dioxygenase, tryptophan 2,3-dioxygenase, oxidative stress, inflammation, molecular docking, natural products

The conclusion matters because older adults are precisely the population in which any chemopreventive effect would be most valuable. Cancer incidence rises steeply with age, and the majority of cancer diagnoses in high-income countries occur in people over 65. If a safe, inexpensive, widely available medication could meaningfully blunt that risk, the public health implications would be enormous. The new summary, formatted as a Bottom Line Summary intended to distill evidence for practicing clinicians, cuts against that hope. Its patient-facing message is blunt: for those age 65 and older, taking a low dose aspirin every day does not lower cancer risk.

To understand why the field arrived at this point, it helps to trace the arc of the aspirin hypothesis. Aspirin, or acetylsalicylic acid, works by irreversibly inhibiting cyclooxygenase enzymes, thereby suppressing production of prostaglandins and thromboxane. That mechanism explains its classic effects on pain, fever, inflammation, and platelet aggregation, and it also supplied a plausible biological route to cancer prevention. Chronic inflammation is a recognized contributor to tumor development, and prostaglandin signaling has been implicated in processes ranging from cell proliferation to angiogenesis. Epidemiologists observed that people who took aspirin regularly appeared to have lower rates of colorectal cancer in particular, and randomized trials designed to test aspirin for cardiovascular prevention began to report, on longer follow-up, apparent reductions in cancer incidence and mortality among those assigned to the drug.

That evidence base, however, was never as clean as the headlines suggested. The randomized trials that generated the most optimistic findings were generally designed and powered to detect cardiovascular events, not cancer, and their cancer results emerged from post hoc analyses with varying durations of follow-up. Observational studies, for their part, are vulnerable to confounding: people who take aspirin regularly differ in many ways from people who do not, including in health-seeking behavior, access to care, and screening rates. When the evidence was assembled systematically, the signal weakened. A 2020 updated systematic review and subgroup meta-analysis of 29 randomized clinical trials of long-term aspirin use for primary cancer prevention, cited in the new summary, examined the totality of trial data and found that the hoped-for protective effect was not consistently supported across cancer types, populations, and doses.

Large randomized trials provided some of the most decisive tests. The ASCEND study, published in the New England Journal of Medicine in 2018, randomized more than 15,000 people with diabetes to aspirin or placebo and found that while aspirin reduced serious vascular events, it also increased major bleeding, and it did not produce the kind of broad benefit that would justify routine use. The JPAD trial in Japanese patients with type 2 diabetes and its ten-year observational follow-up, also published in 2018, examined aspirin’s effects in a diabetic population and found no evidence of a cancer chemopreventive benefit. These trials, conducted in populations at elevated vascular risk who might have been expected to benefit most, consistently failed to demonstrate that low-dose aspirin prevents cancer, while repeatedly confirming its capacity to cause bleeding.

The bleeding issue is central to any risk-benefit calculation. Aspirin’s inhibition of platelet function is permanent for the lifespan of each platelet, and because platelets circulate for roughly a week to ten days, even low doses produce a sustained anti-hemostatic effect. In younger and middle-aged adults this translates into a modest but real excess of gastrointestinal hemorrhage and, less commonly, hemorrhagic stroke. In older adults the risk is amplified: age-related changes in the gastric mucosa, higher prevalence of Helicobacter pylori infection and other comorbidities, greater use of interacting medications such as anticoagulants and nonsteroidal anti-inflammatory drugs, and increased frailty all raise the likelihood that bleeding will be serious rather than merely inconvenient. A prevention strategy that offers no cancer benefit while adding bleeding risk to a 75-year-old is, on its face, difficult to defend.

Professional bodies have been moving in this direction for several years. In the United States, the Preventive Services Task Force in recent guidance narrowed its recommendation on aspirin for primary cardiovascular prevention, declining to recommend initiation in adults 60 and older and suggesting that any decision to start aspirin in adults 40 to 59 at high cardiovascular risk should be individualized. The cancer-prevention rationale, once a secondary argument in favor of aspirin, has largely fallen away as trial evidence accumulated. The new Bottom Line Summary consolidates that shift for the specific question of cancer prevention in older adults, aligning clinical guidance with the randomized evidence rather than with the earlier observational enthusiasm.

The summary also illustrates the value of the evidence-based medicine approach it represents. Rather than relying on mechanistic plausibility or on the accumulated weight of observational associations, Burke and Wheeler, with the SGIM Evidence-Based Medicine Task Force, distilled the randomized trial evidence into a single actionable conclusion. The authors report no funding related to the submission and no conflicts of interest, and the work was reviewed through the SGIM EBM Subcommittee. In a field where enthusiasm for a cheap intervention can outpace the data, such structured syntheses serve as a corrective, translating complex and sometimes contradictory trial literature into guidance that a busy primary care clinician can apply directly in the examination room.

For patients, the practical takeaway is straightforward. People aged 65 and older should not start taking daily low-dose aspirin with the expectation of preventing cancer, and those who are taking it for that purpose have grounds to discuss stopping with their physician. Aspirin retains clear, well-established roles, including in the treatment of pain and fever and in the secondary prevention of cardiovascular events in people who have already had a heart attack or ischemic stroke, where its benefits demonstrably outweigh its risks. What the accumulating evidence has removed is the justification for aspirin as a general-purpose preventive pill in healthy older people. The once-promising idea that a daily tablet could ward off both heart attacks and cancer has, for the older population, been narrowed by the data: the cancer-prevention half of that promise has not survived rigorous testing, and the decision to take aspirin should rest on individualized assessment of cardiovascular benefit against bleeding risk, not on the hope of avoiding a cancer diagnosis.

Subject of Research: Low-dose aspirin for primary cancer prevention in older adults

Article Title: EBM BLS: Low Dose Aspirin Does Not Reduce the Risk of Cancer in Older Adults

Article References: Burke, H. B., & Wheeler, S. G. (2026). EBM BLS: Low Dose Aspirin Does Not Reduce the Risk of Cancer in Older Adults. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10876-8

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10876-8

Keywords: aspirin, cancer prevention, chemoprevention, older adults, geriatrics, primary prevention, evidence-based medicine, randomized trials, bleeding risk, Journal of General Internal Medicine, ASCEND trial, risk-benefit

The headline figure is striking. Compared with lower or no consumption, higher coffee consumption was associated with a pooled relative risk of 0.57, with a 95 percent confidence interval of 0.49 to 0.66. In practical terms, that corresponds to a 43 percent reduction in the risk of oral and pharyngeal cancer among heavier coffee drinkers, and the confidence interval sits entirely below 1.0, meaning the association is statistically significant by conventional standards. In epidemiology, where effect sizes for dietary factors are often modest and easily eroded by confounding, a reduction of this magnitude is unusual and demands attention. It places coffee in the same conversation as other dietary factors that have been linked to head and neck cancer risk, but with an inverse rather than harmful direction.

The methodology behind the estimate reflects the current gold standard for evidence synthesis. The researchers systematically searched PubMed/MEDLINE, Scopus, Web of Science, the Cochrane Library, and Google Scholar from database inception through March 2026, casting a wide net for observational studies that assessed coffee consumption and the risk of oral or pharyngeal cancer. After applying their inclusion criteria, they retained twenty studies. To combine the results, they used a random-effects inverse-variance model with DerSimonian and Laird estimation, a technique that does not assume all studies share a single true effect size but instead models the variability between them. This choice matters, because dietary exposure measurements, population characteristics, and cancer definitions inevitably differ from one study to the next, and a fixed-effect model would have understated that uncertainty.

That variability was real but manageable. The analysis observed moderate heterogeneity across the included studies, quantified by an I-squared statistic of 46.0 percent. Heterogeneity describes how much of the spread in study results reflects genuine differences rather than chance; values below roughly 50 percent are generally considered moderate. In this case, the moderate level suggests that while the studies did not produce identical estimates, they told a broadly consistent story. Crucially, the inverse association between coffee and cancer risk held up when the researchers split the data by geographical region, by study design, and by cancer site, meaning the protective signal was not confined to one continent, one type of study, or one anatomical location within the oral cavity and pharynx.

The authors also took deliberate steps to rule out two of the most common artifacts that plague meta-analyses. Publication bias, the tendency for small studies with dramatic findings to be published more readily than null results, was assessed with Egger’s test, which examines whether smaller studies systematically report larger effects. The result was reassuring: no significant small-study effects were detected, with a p-value of 0.166. Sensitivity analyses, in which individual studies are removed or analytical choices are varied to see whether the pooled estimate wobbles, confirmed the stability of the results. Together, these checks strengthen the case that the observed association is not a statistical mirage created by selective reporting or by the outsized influence of a few outliers.

Why might coffee protect the tissues of the mouth and throat? The biological plausibility rests on well-characterized chemistry. Coffee is one of the richest dietary sources of polyphenols and other bioactive compounds, including chlorogenic acids, caffeic acid, and melanoidins formed during roasting. These molecules exhibit antioxidant activity, neutralizing the reactive oxygen species that can damage DNA in epithelial cells lining the oral cavity and pharynx. They also display anti-inflammatory properties, dampening the chronic inflammation that is increasingly recognized as a driver of carcinogenesis, and antiproliferative effects, slowing the uncontrolled cell division that defines cancer. Some coffee compounds have been shown in laboratory studies to influence phase II detoxification enzymes, enhance DNA repair, and induce apoptosis in pre-malignant cells, offering several mechanistic routes by which a daily beverage could plausibly influence tumor initiation and progression in exposed tissues.

The population-level stakes are considerable. Oral and pharyngeal cancers are major contributors to global cancer-related morbidity and mortality, and their burden is concentrated in regions where tobacco smoking, alcohol consumption, and chewing-related exposures, such as betel quid, are prevalent. Because these cancers are strongly linked to modifiable behaviors, prevention strategies have traditionally focused on tobacco and alcohol control, and rightly so. But the finding that a widely consumed, inexpensive, and socially embedded beverage is associated with markedly lower risk suggests a potential complementary avenue for prevention, particularly in high-burden regions where coffee drinking is culturally established. Unlike novel chemopreventive drugs, coffee requires no new infrastructure, no prescription, and no behavioral revolution.

Yet the researchers are careful, and rightly so, about the limits of what their study can claim. All twenty included studies were observational, meaning they measured what people drank and tracked who developed cancer, rather than randomly assigning coffee in a controlled trial. Observational designs are vulnerable to confounding: coffee drinkers differ from non-drinkers in many ways, including smoking habits, alcohol intake, diet, socioeconomic status, and access to healthcare, and even sophisticated statistical adjustment cannot fully eliminate these differences. Reverse causation is another concern, since early symptoms of disease can change dietary habits before a diagnosis is made. The authors explicitly state that causal inference is limited by the observational nature of the included studies and by variability in how coffee exposure was assessed across studies, which ranged from broad categories to detailed cup-per-day measurements.

That caution should shape how the findings are communicated and consumed. A 43 percent lower risk among coffee drinkers does not mean that drinking coffee will prevent cancer in any individual, nor does it license ignoring the dominant risk factors. Tobacco and alcohol remain overwhelmingly stronger determinants of oral and pharyngeal cancer risk, and no amount of coffee offsets the carcinogenic assault of smoking or heavy drinking. What the meta-analysis provides is a robust, internally consistent observational signal, one that now warrants deeper investigation through cohort studies with detailed exposure assessment, biomarker-based mechanistic research, and, ultimately, trials or natural experiments that can probe causality more directly. It also raises practical questions worth studying, such as whether temperature, preparation method, caffeine content, or additive use modifies the association.

For now, the study adds coffee to a growing list of dietary components, alongside fruits, vegetables, and other polyphenol-rich foods, that are associated with reduced head and neck cancer risk in observational data. The convergence of a large pooled effect, consistency across regions and designs, absence of publication bias, and credible biological mechanisms makes this one of the more compelling dietary-cancer associations reported in recent years. Whether that association survives the scrutiny of randomized evidence remains to be seen, but for the world’s coffee drinkers, the latest science offers an unusually reassuring verdict: the beverage that starts the morning may also, quietly, be defending the tissues it passes on the way down.

Subject of Research: The association between coffee consumption and the risk of oral and pharyngeal cancers

Article Title: Association between coffee consumption and oral and pharyngeal cancers: a systematic review and meta-analysis

Article References: Duan, Y., Guo, M., Mou, T., & Zeng, C. (2026). Association between coffee consumption and oral and pharyngeal cancers: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17132-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17132-6

Keywords: coffee, oral cancer, pharyngeal cancer, meta-analysis, systematic review, cancer prevention, chemoprevention, head and neck cancer, polyphenols, antioxidants, epidemiology, BMC Cancer

The study’s central conclusion is stark: the majority of hospitalisations and deaths among children in their first two years of life are caused by infectious diseases that are, in principle, preventable. Malaria alone accounted for 54.3 percent of all hospital admissions recorded during the follow-up period, dwarfing every other cause of severe illness. Lower respiratory infections ranked second at 16.7 percent of admissions, followed by diarrhoeal disease at 9.6 percent, undernutrition at 7.4 percent and sepsis at 4.8 percent. Among deaths that occurred in hospitals with available medical records, malaria was responsible for 50.6 percent, meaning that one in every two in-hospital deaths in this age group was attributable to a single parasitic disease transmitted by mosquitoes.

The burden extends beyond hospital walls. For children who died outside medical facilities, the research team reconstructed probable causes of death through standardised interviews with family members and caregivers, a well-established epidemiological technique known as verbal autopsy. This analysis likewise identified malaria as the most frequent cause of death, followed by respiratory infections and diarrhoea. The researchers caution, however, that verbal autopsy is likely to underestimate malaria mortality, because the fever and generalised symptoms characteristic of severe malaria overlap considerably with those of other common infectious diseases, making it difficult for bereaved caregivers to distinguish between them when recalling a child’s final illness.

The scale and precision of the study distinguish it from previous efforts to characterise early childhood disease burden in the region. Routine surveillance systems in Sierra Leone and many other countries typically group all children under five into a single reporting category, a practice that obscures the distinct epidemiology of infancy and early toddlerhood and makes it difficult to identify precisely which conditions drive hospitalisation and death at different ages. To close this gap, the ICARIA team combined continuous health facility surveillance with household visits, telephone follow-up and a network of community informants, creating an unusually complete record of both severe illness and mortality across the first two years of life.

“To address this important knowledge gap, we followed 20,560 infants up to 24 months of age across 14 health centres in three districts of Sierra Leone,” explained Kwabena Owusu-Kyei, an ISGlobal researcher based in Sierra Leone and first author of the study. “By combining health facility surveillance with household visits, telephone follow-up and community informants, we were able to build a much more complete picture of childhood hospitalisations and deaths.” During the follow-up period, the cohort recorded 2,688 hospital admissions and 859 deaths, figures that translate into an extraordinary concentration of severe disease in a population of children who had, by the study’s design, access to facilities offering free healthcare.

The context of Sierra Leone’s public health landscape makes the findings all the more consequential. Over the past decade and a half, the country has introduced a series of major initiatives aimed at reducing child deaths, including a policy of free healthcare for children under five, malaria chemoprevention programmes, pneumococcal vaccination and, more recently, the rollout of the malaria vaccine. Yet until now, it has been difficult to assess how these interventions are affecting survival during the first two years of life, the period when children are most vulnerable to the infectious diseases that dominate the region’s disease burden. The new study provides the granular evidence base that such assessments require.

Beyond quantifying the burden of disease, the study identified several factors strongly associated with a child’s chances of survival, offering concrete targets for intervention. Children who had received all the routine vaccines of the Expanded Programme on Immunization (EPI) due for their age had a 35 percent lower risk of overall mortality compared with incompletely vaccinated children. Complete vaccination was also associated with a 29 percent lower likelihood of dying during a hospital admission and, strikingly, a 44 percent lower risk of death in the period after discharge from hospital, a finding that underscores how vaccination status shapes resilience well beyond the immediate protection conferred against specific vaccine-preventable pathogens.

Malaria chemoprevention also emerged as a powerful protective factor. Children who received all scheduled doses of sulfadoxine–pyrimethamine, the preventive antimalarial treatment delivered through Sierra Leone’s immunisation programme, had a 40 percent reduction in mortality risk compared with those who missed doses. Conversely, undernutrition significantly increased the risk of dying during hospitalisation, a result that reinforces long-standing calls to integrate nutritional support into paediatric care rather than treating malnutrition and infectious disease as separate clinical problems. Taken together, these associations suggest that the tools needed to save young lives largely already exist within the health system, but that coverage, adherence and integration remain insufficient.

The study arrives at a moment of broader concern for global child health. Worldwide, child mortality has declined substantially over recent decades, one of the great public health achievements of the modern era, but the progress achieved up to 2015 has since stalled. In many countries across sub-Saharan Africa, infectious diseases remain among the greatest threats to survival during the first years of life, and the stagnation of mortality declines suggests that existing strategies are not reaching their full potential. Sierra Leone, still rebuilding its health system after decades of civil war and the 2014 Ebola epidemic, exemplifies the challenge facing the world’s most vulnerable settings.

“These findings show that there is still a substantial unfinished agenda in global health, and that strengthening vaccination, malaria prevention, community-based care and post-discharge follow-up are essential to reducing child mortality in the world’s most vulnerable settings and meeting the Sustainable Development Goals,” concluded Clara Menéndez, Director of ISGlobal’s Maternal, Child and Reproductive Health Programme and principal investigator of the study. With the Sustainable Development Goal target of ending preventable deaths of newborns and children under five by 2030 drawing closer, the Sierra Leone cohort offers both a warning and a roadmap: the diseases killing the youngest children are known, the preventive tools are available, and the decisive variable is whether they reach every child who needs them.

Subject of Research: Causes of hospitalisation and death from malaria and other infectious diseases in children under two in Sierra Leone

Article Title: Malaria remains the leading cause of hospital admission and in-hospital death in children under two in Sierra Leone

Article References: Malaria remains the leading cause of hospital admission and in-hospital death in children under two in Sierra Leone. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: malaria, child mortality, Sierra Leone, The Lancet Global Health, ISGlobal, ICARIA project, vaccination, chemoprevention, sulfadoxine-pyrimethamine, undernutrition, respiratory infections, verbal autopsy

Hepatocellular carcinoma is one of the deadliest cancers worldwide, and its rise is closely tied to chronic liver injury, cirrhosis, and persistent oxidative damage. Because diagnosis often comes late and treatment options are limited, scientists have long been interested in chemoprevention, the idea that compounds taken before disease develops can interrupt the earliest steps of tumor formation. Curcumin has attracted decades of attention for its anti-inflammatory and antioxidant behavior, but it suffers from notoriously poor absorption in the gut. Piperine has a well-documented ability to boost the bioavailability of curcumin, which is why the two are so frequently paired in both traditional cuisine and modern experimental design. The new study set out to test whether that pairing could do more than improve uptake, and whether it could measurably alter the biology of a developing liver tumor.

To model the disease, the researchers induced hepatocellular carcinoma in rats using a two-hit protocol that mirrors how human liver cancer often arises from accumulated toxic insults. Animals first received diethylnitrosamine, or DEN, a potent carcinogen that damages DNA and initiates malignant transformation in hepatocytes. This was followed by thioacetamide, or TAA, a compound that produces repeated cycles of liver injury, fibrosis, and regeneration, creating the inflamed, scarred environment in which initiated cells can proliferate into full tumors. The regimen ran for twenty weeks, a period long enough for tumor burden to become established and measurable. Alongside this carcinogenic exposure, separate groups of rats received oral pretreatment with curcumin alone, piperine alone, or the two compounds in combination, given throughout the entire experimental period.

The damage in the untreated carcinogen group was exactly what the model predicts. Rats exposed to DEN and TAA showed increased tumor burden, sharply elevated liver enzymes in the serum, and a biochemical signature of a liver under siege. Lipid peroxidation, the oxidative degradation of cell membranes, climbed as reactive oxygen species overwhelmed the tissue. The liver’s own antioxidant defenses, the enzymatic systems that normally neutralize free radicals, were depleted. Alpha-fetoprotein, a classic tumor marker for hepatocellular carcinoma, rose in the bloodstream, and interleukin-6, a pro-inflammatory signaling molecule implicated in cancer-promoting chronic inflammation, was elevated as well. Under the microscope, the liver architecture was severely distorted, with the organized lobular structure of healthy tissue replaced by the disarray of injury and nodular transformation.

The treatment groups told a strikingly different story. Rats that received curcumin, and to a greater extent those that received curcumin and piperine together, showed improved levels of the key serum biomarkers, better antioxidant status, and reduced lipid peroxidation. Histopathological examination revealed that the normal tissue structure was substantially restored rather than progressively destroyed. In practical terms, the compounds did not merely mask the damage in blood tests; the livers themselves looked measurably healthier. The combination regimen emerged as the most effective intervention, consistent with the idea that piperine’s enhancement of curcumin’s bioavailability translates into a stronger biological effect when the two are administered together.

The mechanistic heart of the paper lies in what the team found when they probed the TBP2–ASK1–JNK–caspase-3 axis in liver tissue. This signaling cascade begins with TBP2, a thioredoxin-binding protein that responds to oxidative stress, and passes through ASK1, a mitogen-activated protein kinase kinase kinase also known as MAP3K5, which becomes activated when its inhibitory thioredoxin partner is oxidized and released. Activated ASK1 phosphorylates downstream JNK, the c-Jun N-terminal kinase, which in turn influences the mitochondrial pathway of apoptosis, ultimately engaging caspase-3, the executioner enzyme that dismantles the cell. In the carcinogen-exposed rats, this axis was dysregulated, a disruption that matters because the balance of this pathway determines whether damaged cells are eliminated by programmed cell death or allowed to survive and accumulate the mutations that drive cancer.

Preventive treatment with curcumin and piperine normalized the expression of the proteins in this cascade, restoring a pattern of cellular signaling and apoptosis closer to that of healthy liver tissue. The authors interpret this as evidence that the chemopreventive effect of the compounds is not a vague antioxidant blanket but a targeted modulation of a defined stress-response pathway. By damping the oxidative stress that activates ASK1 and rebalancing the apoptotic machinery downstream, the treatment appears to preserve the liver’s ability to clear damaged cells while reducing the inflammatory and peroxidative conditions that fuel tumor growth. Immunohistochemistry and Western blotting provided complementary confirmation, mapping where in the tissue the protein changes occurred and quantifying their abundance.

The study was conducted with formal ethical oversight, approved by the Institutional Animal Ethics Committee of Jamia Hamdard under the guidelines of India’s Committee for the Purpose of Control and Supervision of Experiments on Animals, and the work followed ARRIVE reporting standards for animal research. Data were analyzed by one-way analysis of variance followed by Tukey’s post hoc test, with results considered statistically significant at a threshold of p less than 0.05. The authors received no external funding for the study, and the first author was supported by a Junior Research Fellowship from the University Grants Commission. The article was published open access on 9 October 2026, making the full dataset and methods available to researchers anywhere without a subscription.

As with any animal study, the usual caveats apply. A rat model of chemically induced liver cancer, however well constructed, does not reproduce every feature of human hepatocellular carcinoma, which typically develops over decades against a backdrop of viral hepatitis, alcohol-related injury, or metabolic dysfunction. Doses used in laboratory animals often exceed what a person could reasonably obtain from diet alone, and curcumin’s low bioavailability remains a genuine obstacle to clinical translation even when piperine is present. The authors are careful to frame the findings as chemopreventive and hepatoprotective effects observed in an experimental model, associated with modulation of the TBP2–ASK1–JNK–caspase-3 axis, rather than as a demonstrated therapy for established human tumors.

Nevertheless, the study adds a meaningful piece to a growing body of evidence that dietary bioactive compounds can act on specific, measurable molecular targets rather than exerting only diffuse antioxidant effects. If the TBP2–ASK1–JNK–caspase-3 axis proves to be similarly dysregulated in human liver disease, the curcumin–piperine combination, or optimized derivatives of it, could become candidates for controlled trials aimed at preventing the progression of chronic liver injury toward cancer. For now, the image is an appealing one: two molecules that have traveled together through human kitchens for centuries, shown under the strict lens of modern molecular biology to coordinate a defense of the liver’s most vulnerable signaling machinery. The next step will be determining whether that defense survives the journey from the rat liver to the clinic.

Subject of Research: Chemoprevention of hepatocellular carcinoma by curcumin and piperine through modulation of the TBP2–ASK1–JNK–caspase-3 axis in rats

Article Title: Curcumin and piperine modulate the TBP2-ASK1-JNK-caspase-3 axis associated with prevention of DEN and TAA-induced hepatocellular carcinoma in rats

Article References: Afroz, N., Vafa, A., Ghosh, R., Rahaman, P. F., Wajid, S., & Ahmad, A. (2026). Curcumin and piperine modulate the TBP2-ASK1-JNK-caspase-3 axis associated with prevention of DEN and TAA-induced hepatocellular carcinoma in rats. BMC Cancer. https://doi.org/10.1186/s12885-026-17037-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17037-4

Keywords: curcumin, piperine, hepatocellular carcinoma, chemoprevention, liver cancer, oxidative stress, ASK1, JNK, caspase-3, apoptosis, diethylnitrosamine, thioacetamide

Lynch syndrome arises from inherited mutations in DNA mismatch repair genes, leaving affected individuals with a significantly elevated lifetime risk of colorectal cancer as well as several other malignancies. For this population, prevention is not an abstract concept but a daily reality shaped by intensive surveillance programs, genetic counseling, and difficult decisions about risk-reducing interventions. The scientific case for aspirin in this context has been building for years. The landmark CAPP2 study demonstrated that acetylsalicylic acid can significantly reduce the long-term risk of colorectal cancer in people with Lynch syndrome, using a comparatively high daily dose of 600 milligrams. That evidence positioned aspirin as one of the few chemopreventive agents with robust data in a hereditary cancer setting, offering a low-cost, widely accessible complement to regular colonoscopic surveillance.

The picture grew even more promising with the recently published international CaPP3 study, which suggests that a much lower dose of 100 milligrams daily could deliver a similar cancer-preventive effect while causing fewer side effects, and in particular fewer bleeding complications, which have long been the principal concern associated with long-term aspirin use. The prospect of a practical, better-tolerated regimen is significant for a group that must weigh preventive benefit against decades of continuous medication. Dr. Robert Hüneburg, corresponding author of the new study and a senior physician at Medical Clinic I at the UKB who also conducts research at the University of Bonn, urged measured interpretation of the dose comparison. Since the statistical criteria for formal equivalence between the two studies were not met in all analyses, he noted, the results should still be interpreted with some caution. However, he added, the CaPP3 findings suggest that 100 milligrams daily could be a practical and better-tolerated option for many patients.

Against this backdrop of evolving evidence, the Bonn team set out to measure how much of the science has actually reached clinical practice. The LYNX survey enrolled 539 people with Lynch syndrome from across Germany and was designed before the publication of the CaPP3 results, then conducted between December 2025 and February 2026. That timing matters for interpretation: the responses reflect the use of acetylsalicylic acid based on the scientific evidence available at the time of the survey, primarily the higher-dose CAPP2 findings. Hüneburg emphasized that future studies must show whether the new findings on lower dosages will contribute to acetylsalicylic acid being used more frequently for cancer prevention. In other words, the survey captures a snapshot of care under the old evidence regime, and the lower-dose data may yet shift the calculus for both physicians and patients.

What the survey revealed was not ignorance or apathy but a paradox. Awareness of established prevention measures among respondents was exceptionally high: about 97 percent were familiar with the specific screening recommendations for Lynch syndrome, and nearly all undergo regular colonoscopies. Adherence to surveillance, the cornerstone of Lynch syndrome care, is therefore excellent. Yet when it came to aspirin, the numbers collapsed. Only 10.4 percent of respondents reported currently taking acetylsalicylic acid, and just 6.9 percent of the entire group specifically used it for cancer prevention in the context of Lynch syndrome. For a population in which a well-studied, inexpensive preventive agent exists, those figures represent a profound gap between evidence and everyday care.

The reasons patients gave for avoiding aspirin were revealing. According to Dr. Anne-Sophie Layritz, co-first author of the study and an assistant physician at Medical Clinic I at the UKB, the main reasons cited were a lack of prior engagement with the topic, concerns about side effects, and uncertainty regarding the scientific evidence. Each of these barriers points to a different failure point in the care pathway. A lack of engagement suggests that the topic is simply not being raised consistently during counseling appointments. Concerns about side effects reflect legitimate worries about gastrointestinal bleeding that the lower-dose CaPP3 data may help address. Uncertainty about the evidence indicates that patients perceive the scientific picture as unsettled, a perception that clearer, more structured communication from care teams could correct. None of these barriers suggests resistance to prevention itself.

Indeed, the same survey documented remarkable enthusiasm for novel preventive approaches. About three-quarters of respondents could, in principle, imagine participating in a study on a preventive mRNA cancer vaccine, a technology that has moved from pandemic fame to the frontier of oncology. After receiving additional information about the concept, that proportion rose to about 80 percent. More strikingly, more than 92 percent stated that they would want to receive such a vaccine if it were approved in the future. A majority of participants also accepted the possibility of being assigned to a placebo group in such trials and the inherent risk of side effects, both of which are common sticking points in clinical trial recruitment. Nicola Reents, co-first author of the study representing SemiColon, said these results show just how great the interest is among those affected in innovative prevention options and in actively participating in research.

Taken together, the LYNX findings do not indicate any fundamental reluctance toward cancer prevention among people with Lynch syndrome. Instead, the authors describe a significant implementation gap between scientific evidence, medical counseling, and actual application. The community is demonstrably willing to embrace prevention, whether through established tools like colonoscopy or through future innovations like mRNA vaccines, but the translation of aspirin data into routine counseling has lagged. According to the authors, early, understandable, and structured information, together with an individualized assessment of benefits and risks, is crucial to closing that gap. As the lower-dose evidence matures, the window is open for care teams to revisit how chemoprevention is discussed, ensuring that patients receive balanced, up-to-date guidance rather than leaving aspirin’s potential benefits unexamined.

The collaborative design of the study itself offers a model for how such gaps might be bridged. Support from the centers of the German Consortium Familial Colorectal Cancer and the partnership with the self-help organization SemiColon were of central importance to the project, allowing the researchers to reach many affected individuals and to contextualize both the research questions and the results from the patients’ perspective. Reents of SemiColon served as a co-first author of the publication, an unusual and telling arrangement that embedded the patient voice directly into the research process. Hüneburg emphasized that the project is a very good example of research that is conducted not just about, but together with, those affected. For a condition in which lifelong engagement with prevention determines outcomes, that participatory approach may prove as consequential as any single clinical finding, pointing toward a future in which the evidence, the counseling, and the patient’s own informed decision finally align.

Subject of Research: Aspirin chemoprevention uptake among people with Lynch syndrome

Article Title: Aspirin rarely used for colorectal cancer prevention

Article References: Aspirin rarely used for colorectal cancer prevention. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Lynch syndrome, colorectal cancer, aspirin, chemoprevention, CAPP2 study, CaPP3 study, cancer prevention, mRNA cancer vaccine, implementation gap, genetic predisposition, University Hospital Bonn, patient survey

The research, led by first author Ahmet Kılınç of the General Surgery Department at Elmalı State Hospital in Antalya, with corresponding author Mehmet Eşref Ulutaş and colleagues including Çiğdem Damla Deniz, Haydar Öztaş, İsmail Hasırcı, and Adil Kartal, was designed to test honey in two distinct modes: prophylaxis and therapy. Rather than studying established, late-stage tumors, the investigators focused on the very beginning of the disease process, when pancreatic tissue first begins to drift toward malignancy. This choice matters because pancreatic cancer is usually diagnosed late, and any intervention that could act at the precursor stage would be of enormous clinical interest if it could ever be translated to humans.

To model the disease, the team used the azaserine-rat model, a well-established experimental system in pancreatic cancer research. Azaserine is a chemical carcinogen that, when administered to rats, reliably induces lesions in the pancreas that mirror the early steps of human pancreatic tumor formation. The key structures the researchers tracked are called atypical acinar cell foci, or AACF, which are microscopic clusters of abnormal acinar cells regarded as precursor lesions of pancreatic cancer. Because these foci appear early, are quantifiable under the microscope, and correlate with later tumor burden, they serve as sensitive surrogate endpoints for chemoprevention studies, allowing researchers to measure an intervention’s effect long before overt tumors would develop.

The experimental design divided the animals into five groups: a control group, a honey-only group, an azaserine group that received the carcinogen alone, a therapeutic group, and a prophylactic group. The distinction between the last two is central to the study’s message. In the prophylactic group, honey was administered at the same time as azaserine, testing whether the substance could protect pancreatic tissue while it was being assaulted by the carcinogen. In the therapeutic group, honey was started three weeks after azaserine administration, a delay designed to simulate a more clinically realistic scenario in which the disease process is already underway before treatment begins. After eleven weeks of follow-up, the animals were sacrificed and their pancreatic tissues removed for detailed histopathological examination.

The quantitative readout of the study was rigorous. The researchers did not simply report whether lesions were present or absent; they measured three separate morphometric parameters of the atypical acinar cell foci. The first was the number of focus intersections per unit area, essentially a density measure of how many precursor lesions were packed into a given region of pancreatic tissue. The second was the ratio of the total AACF size to the size of the whole pancreas, capturing how much of the organ had been overtaken by abnormal cells. The third was the estimated number of foci per unit volume, a stereological estimate that corrects for the fact that a two-dimensional tissue section underestimates three-dimensional lesion burden. Together, these metrics provide a multidimensional picture of how extensively the carcinogen had transformed the pancreas in each group.

The results were consistent across both intervention arms. In the prophylactic group, all three quantitative measures of AACF were significantly lower than in the azaserine-only group, with statistical significance reported at p < 0.05. Critically, the therapeutic group, in which honey was introduced only after the carcinogenic process had been initiated, showed the same pattern of significant reduction. This means the honey did not merely shield healthy tissue from damage; it also appeared to slow or partially reverse the progression of lesions that had already begun to form. In parallel, the researchers compared serum levels of cancer antigen 19-9, the most widely used clinical biomarker for pancreatic cancer, and C-reactive protein, a general marker of inflammation, across the groups, adding a biochemical dimension to the histological findings.

What might explain such an effect? Honey is not a single compound but a chemically intricate matrix containing hundreds of substances, including polyphenols, flavonoids, hydrogen peroxide generated by the enzyme glucose oxidase, methylglyoxal, organic acids, and trace elements. Many of these constituents have documented antioxidant and anti-inflammatory activities in laboratory systems, and oxidative stress and chronic inflammation are recognized drivers of pancreatic carcinogenesis. Quercus pyrenaica honey, derived from an oak species native to parts of Europe and Anatolia, may possess a particularly favorable composition of these bioactive molecules, although the study did not perform a full chemical characterization of the honey used. The authors are careful to frame their work as a foundation for further investigation rather than a demonstration of mechanism.

The study’s limitations are those inherent to any animal experiment. The azaserine model, while valuable, does not recapitulate every feature of human pancreatic ductal adenocarcinoma, the most common and deadliest form of the disease in patients. Doses, timing, and species differences all complicate extrapolation to human beings, and the eleven-week follow-up window captures precursor lesions rather than invasive cancer or survival outcomes. The authors themselves acknowledge that their conclusions will gain real significance only if supported by clinical studies in this field. There is also the practical question of standardization: honey varies enormously by floral source, season, and geography, so any future therapeutic application would require rigorous quality control of the active constituents.

Nevertheless, the dual prophylactic and therapeutic signal is what makes the study notable. Many candidate chemopreventive agents show protection only when given before carcinogen exposure, a scenario with little clinical relevance, since people at risk of pancreatic cancer cannot usually be identified early enough. Demonstrating an effect when treatment begins after tumor initiation suggests that the bioactive components of Quercus pyrenaica honey may influence processes such as cell proliferation, apoptosis, or inflammation within already-transformed tissue, not just antioxidant shielding of healthy cells. If subsequent work identifies the responsible compounds and their molecular targets, it could open a path toward standardized extracts rather than raw honey as an intervention.

The research, which received ethics approval from the KONÜDAM Animal Ethics Committee of Necmettin Erbakan University and was conducted in accordance with the Declaration of Helsinki, was published open access with no external funding and no declared competing interests. For now, the message for the public is one of cautious fascination rather than immediate action: no one should interpret these findings as a reason to self-treat with honey, and patients with pancreatic disease should continue to rely on evidence-based oncological care. But the study adds a compelling data point to the argument that natural products deserve systematic scientific scrutiny, and it demonstrates that even a substance as ancient and familiar as honey can still surprise researchers when put to a properly controlled experimental test.

Subject of Research: Anti-tumoral effects of Quercus pyrenaica honey in an experimental rat model of pancreatic cancer

Article Title: Investigation of the anti-tumoral effect of honey in experimental pancreatic cancer

Article References: Kılınç, A., Ulutaş, M. E., Deniz, Ç. D., Öztaş, H., Hasırcı, İ., & Kartal, A. (2026). Investigation of the anti-tumoral effect of honey in experimental pancreatic cancer. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05565-2

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05565-2

Keywords: honey, pancreatic cancer, Quercus pyrenaica, azaserine rat model, atypical acinar cell foci, CA 19-9, C-reactive protein, chemoprevention, experimental oncology, natural products, complementary medicine, preclinical research